Gefitinib for oesophageal cancer progressing after chemotherapy (COG): a phase 3, multicentre, double-blind, placebo-controlled randomised trial.

Gefitinib for oesophageal cancer progressing after chemotherapy (COG): a phase 3, multicentre, double-blind, placebo-controlled randomised trial.

BACKGROUND: Evidence is scarce for the effectiveness of therapies for oesophageal cancer progressing after chemotherapy, and no randomised trials have been reported. We aimed to compare gefitinib with placebo in previously treated advanced oesophageal cancer. METHODS: For this phase 3, parallel, ran...

Full description

Bibliographic Details
Main Authors: Dutton, S, Ferry, D, Blazeby, J, Abbas, H, Dahle-Smith, A, Mansoor, W, Thompson, J, Harrison, M, Chatterjee, A, Falk, S, Garcia-Alonso, A, Fyfe, D, Hubner, R, Gamble, T, Peachey, L, Davoudianfar, M, Pearson, S, Julier, P, Jankowski, J, Kerr, R, Petty, R
Format: Journal article
Language:English
Published: Elsevier 2014

Similar Items